Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00014170 · ClinicalTrials.gov registry record · Phase 2
Gefitinib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 92
- Enrollment target
NCT00014170: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00014170 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 92 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00014170, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 92 participants
- Enrollment target
Study Summary
Biological therapies such as gefitinib may interfere with the growth of the tumor cells and slow the growth of glioblastoma multiforme. Phase II trial to study the effectiveness of gefitinib in treating patients who have newly diagnosed glioblastoma multiforme.
Interventions
- OTHER laboratory biomarker analysis
- OTHER questionnaire administration
- PROCEDURE quality-of-life assessment
- OTHER pharmacological study
- DRUG gefitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2001-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00014170
The ClinicalTrials.gov registry entry for NCT00014170 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 92 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which laboratory biomarker analysis is the first listed.
NCT00014170 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00014170 about?
NCT00014170 is a clinical study titled "Gefitinib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme". Biological therapies such as gefitinib may interfere with the growth of the tumor cells and slow the growth of glioblastoma multiforme. Phase II trial to study the effectiveness of gefitinib in treating patients who have newly diagnosed glioblastoma multiforme.
What is the current status of trial NCT00014170?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 92 participants. The study started on 2001-03.
What interventions are being tested in trial NCT00014170?
The interventions under investigation include: laboratory biomarker analysis (OTHER), questionnaire administration (OTHER), quality-of-life assessment (PROCEDURE), pharmacological study (OTHER), gefitinib (DRUG).
Who is sponsoring clinical trial NCT00014170?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.